GlassScriptPhysician profile
Jacob N Stein
NPI 1104244300
$6,298.19
in general payments reported to CMS, 2019-2025
26 companies · $1,557 in 2025
The $1,557 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $357 · 2021: $406 · 2022: $768 · 2023: $1,028 · 2024: $1,816 · 2025: $1,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,401.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,226.19 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $854.08 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $497.04 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $458.53 | 2022-2025 | Lybalvi, Aristada |
| Almatica Pharma LLC | $454.43 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Corium, LLC | $417.51 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $412.01 | 2019-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $356.33 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $225.03 | 2022-2025 | Caplyta |
| Lundbeck LLC | $220.03 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $181.75 | 2024-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $161.49 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $155.02 | 2023-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $115.43 | 2021-2025 | Qelbree, Qelbree |
| Allergan, INC. | $95.18 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $77.09 | 2024-2025 | Relexxii |
| Teva Pharmaceuticals USA, INC. | $57.44 | 2019-2025 | Austedo Xr |
| Noven Therapeutics, LLC | $56.44 | 2024 | Xelstrym |
| Bausch Health US, LLC | $51.15 | 2022-2023 | Aplenzin |
| Idorsia Pharmaceuticals US INC | $44.09 | 2023-2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $38.62 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $35.80 | 2024-2025 | Cobenfy |
| Alfasigma USA, INC. | $32.92 | 2020-2021 | |
| Shire North American Group INC | $32.23 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.57 | 2025 | Spravato |
| Tempus Ai, INC | $17.79 | 2025 | Tempus Pixel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.